10x Genomics - TXG Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TXG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXG, but not buy additional shares or sell existing shares.
View TXG analyst ratings or view top-rated stocks.

9 equities research analysts have issued twelve-month target prices for 10x Genomics' stock. Their TXG share price forecasts range from $25.00 to $65.00. On average, they expect the company's stock price to reach $51.00 in the next twelve months. This suggests a possible upside of 4.8% from the stock's current price.
View analysts price targets for TXG or view top-rated stocks among Wall Street analysts.

10x Genomics' stock was trading at $36.44 at the beginning of 2023. Since then, TXG stock has increased by 33.5% and is now trading at $48.65.
View the best growth stocks for 2023 here.

10x Genomics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 6,200,000 shares, a decline of 16.9% from the December 31st total of 7,460,000 shares. Based on an average daily volume of 1,360,000 shares, the days-to-cover ratio is currently 4.6 days. Currently, 7.2% of the shares of the company are sold short.
View 10x Genomics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our TXG earnings forecast.

10x Genomics will be holding an earnings conference call on Wednesday, February 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

10x Genomics, Inc. (NASDAQ:TXG) issued its quarterly earnings data on Wednesday, November, 2nd. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The company had revenue of $131.10 million for the quarter, compared to analyst estimates of $129.13 million. 10x Genomics had a negative trailing twelve-month return on equity of 21.01% and a negative net margin of 33.20%. The business's quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.15) earnings per share.

10x Genomics updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $500.00 million-$520.00 million, compared to the consensus revenue estimate of $509.87 million.

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

(TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager.

10x Genomics trades on the NASDAQ under the ticker symbol "TXG."

10x Genomics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (7.52%), ARK Investment Management LLC (3.77%), Financial Consulate Inc. (0.14%), Nordwand Advisors LLC (0.12%), Allworth Financial LP (0.02%) and Capricorn Fund Managers Ltd (0.01%). Insiders that own company stock include Associates Vi LP Venrock, Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, Bryan E Roberts, Foresite Capital Management I,, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends.

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TXG stock can currently be purchased for approximately $48.65.

10x Genomics (NASDAQ:TXG) has a market capitalization of $5.57 billion and generates $490.49 million in revenue each year. The company earns $-58,220,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis.

The company employs 1,239 workers across the globe.

10x Genomics' mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The official website for the company is www.10xgenomics.com. The company can be reached via phone at 925-401-7300 or via email at investors@10xgenomics.com.